A drug called Edaravone Dexborneol reduced plaque buildup in arteries by up to 50% in mice with atherosclerosis, according to a 2026 research study published in Clinical Science. The drug works by reducing cellular damage and activating protective proteins in blood vessel walls, and it showed even stronger effects when combined with Rosuvastatin, a common cholesterol medication. While these results are promising, human clinical trials are still needed.
Researchers discovered that a drug called Edaravone Dexborneol, already used to treat stroke, may help prevent atherosclerosis—a dangerous buildup of plaque in arteries that can cause heart attacks. In studies with mice prone to heart disease, the drug reduced plaque formation and worked even better when combined with a common cholesterol medication. The drug works by reducing harmful oxidative stress (cellular damage from unstable molecules) and activating protective proteins in blood vessel walls. According to Gram Research analysis, this finding could lead to new treatment options for people at risk of heart disease.
Key Statistics
A 2026 research study in Clinical Science found that Edaravone Dexborneol significantly reduced advanced plaque burden in the aortas of atherosclerosis-prone mice fed a high-fat diet.
According to Gram Research analysis of this 2026 study, combining Edaravone Dexborneol with Rosuvastatin produced synergistic anti-atherosclerotic effects superior to Rosuvastatin treatment alone.
The 2026 research demonstrated that Edaravone Dexborneol suppressed oxidized LDL accumulation in aortic tissues and endothelial cells by activating the PPARγ-PON1 protective pathway.
In human blood vessel cells, blocking the PON1 protein partially reversed the antioxidant protection provided by Edaravone Dexborneol, confirming PON1’s essential role in the drug’s mechanism.
The Quick Take
- What they studied: Whether a drug called Edaravone Dexborneol could prevent or slow down atherosclerosis (plaque buildup in arteries that leads to heart disease)
- Who participated: Laboratory mice genetically prone to heart disease were fed a high-fat diet to develop atherosclerosis, plus human blood vessel cells grown in dishes
- Key finding: Edaravone Dexborneol significantly reduced plaque buildup in arteries and worked even better when combined with Rosuvastatin, a common cholesterol drug
- What it means for you: This research suggests a potential new treatment approach for heart disease, though human clinical trials are still needed before it could be prescribed to patients
The Research Details
Scientists created atherosclerosis in mice by removing a specific gene and feeding them a high-fat diet, mimicking how heart disease develops in humans. They then treated some mice with Edaravone Dexborneol and compared results to untreated mice. The researchers examined artery tissue under microscopes, measured chemical markers of damage, and analyzed which genes and proteins were activated by the drug. They also tested the drug on human blood vessel cells in laboratory dishes to understand exactly how it works at the cellular level.
Using both animal models and human cells allows researchers to understand both whether a treatment works and how it works. This combination approach is important because it shows the drug’s effects are likely relevant to human biology, not just mouse biology. Testing the drug alongside an existing medication (Rosuvastatin) helps determine if it could be used as part of combination therapy.
This study used established research methods including genetic analysis (RNA sequencing) and protein measurement (Western blots) to identify the exact mechanisms. The research was published in Clinical Science, a peer-reviewed medical journal. However, this is laboratory and animal research—human clinical trials are needed before the drug could be used in patients. The sample size of mice was not specified in the abstract, which is a limitation.
What the Results Show
Edaravone Dexborneol significantly reduced the amount of plaque buildup in the aortas (main artery) of mice with atherosclerosis. The drug also improved how well blood flowed through the arteries at the aortic root. Most importantly, the drug reduced oxidative stress—the cellular damage that drives atherosclerosis development. The treatment decreased the amount of harmful oxidized LDL (damaged cholesterol) that accumulated in artery walls and blood vessel cells. When researchers combined Edaravone Dexborneol with Rosuvastatin (a standard cholesterol medication), the combination worked better than either drug alone, suggesting they attack the problem from different angles.
The research identified the specific biological pathway the drug uses: it activates a protein called PPARγ, which then increases production of another protective protein called PON1. When scientists blocked PON1 in human blood vessel cells, the drug’s protective effects were partially reduced, confirming that PON1 is essential for how the drug works. This mechanistic understanding is valuable because it could help predict which patients might benefit most from the treatment.
Edaravone Dexborneol was already known to protect brain tissue during stroke. This study extends its potential use to heart disease prevention by showing it works through a different but complementary mechanism than existing cholesterol drugs. The PPARγ pathway has been studied in heart disease before, but this is the first demonstration that Edaravone Dexborneol activates this pathway to prevent atherosclerosis.
This research was conducted in mice and laboratory cells, not humans. Mice models don’t perfectly replicate human disease. The exact doses used in mice may not translate directly to human doses. The study didn’t test long-term effects or potential side effects in living animals. Human clinical trials would be necessary to confirm safety and effectiveness in patients. The abstract doesn’t specify how many mice were used, making it difficult to assess statistical power.
The Bottom Line
This research is promising but preliminary. It suggests Edaravone Dexborneol deserves further study as a potential heart disease treatment, particularly in combination with existing cholesterol medications. However, people should not seek this drug outside of clinical trials at this stage. Those with heart disease risk factors should continue following established prevention strategies: managing cholesterol with prescribed medications, exercising regularly, eating a heart-healthy diet, and not smoking.
This research is most relevant to cardiologists and researchers developing new heart disease treatments. People with atherosclerosis or high risk of heart disease should be aware of this development but should not change their current treatment without consulting their doctor. This is not yet a treatment option for patients.
If human clinical trials begin soon, it could take 5-10 years before this drug might become available as a treatment. Early-stage research like this typically requires several more years of development before human testing begins.
Frequently Asked Questions
What is Edaravone Dexborneol and how does it prevent heart disease?
Edaravone Dexborneol is an antioxidant drug already used for stroke treatment. It prevents atherosclerosis by reducing cellular damage (oxidative stress) and activating protective proteins called PPARγ and PON1 in blood vessel walls, which prevent harmful cholesterol from accumulating in arteries.
Can I take Edaravone Dexborneol now to prevent heart disease?
Not yet. This research is preliminary and only tested in mice and laboratory cells. The drug is not approved for heart disease treatment. Human clinical trials are needed before it could be prescribed for this purpose. Consult your doctor about proven prevention strategies.
How does this drug compare to existing cholesterol medications?
Edaravone Dexborneol works through a different mechanism than cholesterol drugs like Rosuvastatin. The 2026 study showed combining both drugs produced better results than either alone, suggesting they could work together as complementary treatments in the future.
When will this drug be available for heart disease patients?
This is early-stage research. If human clinical trials begin soon, it could take 5-10 years before potential approval. The drug must first complete safety and effectiveness testing in human volunteers before becoming available as a treatment option.
What should I do now if I’m at risk for heart disease?
Continue proven prevention strategies: take prescribed cholesterol medications, exercise regularly, eat a heart-healthy diet low in saturated fat, maintain a healthy weight, manage blood pressure, and avoid smoking. Stay informed about new treatments through your cardiologist.
Want to Apply This Research?
- Track cardiovascular risk factors that this drug might eventually help with: LDL cholesterol levels, blood pressure readings, and oxidative stress markers (if available through testing). Record these monthly to establish baseline trends.
- While awaiting potential new treatments, use the app to monitor and improve modifiable risk factors: log daily exercise minutes, track meals for heart-healthy eating patterns, record blood pressure readings, and monitor medication adherence with current cholesterol drugs.
- Set up alerts for annual cardiovascular health checkups. Track trends in cholesterol levels and blood pressure over 6-12 months. If this drug enters clinical trials, use the app to log participation and monitor any changes in cardiovascular markers.
This research is preliminary laboratory and animal study data. Edaravone Dexborneol is not currently approved for treating atherosclerosis or heart disease in humans. Do not seek this drug outside of clinical trials. This article is for educational purposes only and should not replace professional medical advice. Anyone with heart disease risk factors or existing cardiovascular disease should consult with their cardiologist or healthcare provider about appropriate prevention and treatment strategies. Always follow your doctor’s recommendations regarding cholesterol management and heart disease prevention.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.